126 related articles for article (PubMed ID: 19641653)
21. Coxsackievirus B3 infection leads to cell death of cardiac myocytes.
Herzum M; Ruppert V; Küytz B; Jomaa H; Nakamura I; Maisch B
J Mol Cell Cardiol; 1994 Jul; 26(7):907-13. PubMed ID: 7966359
[TBL] [Abstract][Full Text] [Related]
22. ER
Huber S
J Clin Cell Immunol; 2015; 6(6):1-9. PubMed ID: 26925301
[TBL] [Abstract][Full Text] [Related]
23. Nitric oxide and murine coxsackievirus B3 myocarditis: aggravation of myocarditis by inhibition of nitric oxide synthase.
Hiraoka Y; Kishimoto C; Takada H; Nakamura M; Kurokawa M; Ochiai H; Shiraki K
J Am Coll Cardiol; 1996 Nov; 28(6):1610-5. PubMed ID: 8917278
[TBL] [Abstract][Full Text] [Related]
24. Coxsackievirus B-3 myocarditis. Acute and chronic forms of the disease caused by different immunopathogenic mechanisms.
Lodge PA; Herzum M; Olszewski J; Huber SA
Am J Pathol; 1987 Sep; 128(3):455-63. PubMed ID: 2957924
[TBL] [Abstract][Full Text] [Related]
25. T cell-mediated immune response enhances the severity of myocarditis in secondary cardiotropic virus infection in mice.
Kishimoto C; Hiraoka Y; Takada H
Basic Res Cardiol; 2001 Sep; 96(5):439-45. PubMed ID: 11605990
[TBL] [Abstract][Full Text] [Related]
26. Role of CD1d in coxsackievirus B3-induced myocarditis.
Huber S; Sartini D; Exley M
J Immunol; 2003 Mar; 170(6):3147-53. PubMed ID: 12626572
[TBL] [Abstract][Full Text] [Related]
27. Enteroviral infection of mice with severe combined immunodeficiency. Evidence for direct viral pathogenesis of myocardial injury.
Chow LH; Beisel KW; McManus BM
Lab Invest; 1992 Jan; 66(1):24-31. PubMed ID: 1309927
[TBL] [Abstract][Full Text] [Related]
28. The effects of lobenzarit disodium, a novel immunomodulator, upon murine coxsackievirus B3 myocarditis.
Takada H; Kishimoto C; Kuroki Y; Matsushita I; Hiraoka Y; Kurokawa M; Ochiai H; Sasayama S
Heart Vessels; 1993; 8(2):59-66. PubMed ID: 8390975
[TBL] [Abstract][Full Text] [Related]
29. Modulation of cytokine expression by CD4+ T cells during coxsackievirus B3 infections of BALB/c mice initiated by cells expressing the gamma delta + T-cell receptor.
Huber SA; Mortensen A; Moulton G
J Virol; 1996 May; 70(5):3039-44. PubMed ID: 8627781
[TBL] [Abstract][Full Text] [Related]
30. Characterization of a murine model of myocarditis induced by a reactivated coxsackievirus B3.
Zhang H; Yousef GE; Ouyang X; Archard LC
Int J Exp Pathol; 1994 Apr; 75(2):99-110. PubMed ID: 8199011
[TBL] [Abstract][Full Text] [Related]
31. Early Treatment of Coxsackievirus B3-Infected Animals With Soluble Coxsackievirus-Adenovirus Receptor Inhibits Development of Chronic Coxsackievirus B3 Cardiomyopathy.
Pinkert S; Dieringer B; Klopfleisch R; Savvatis K; Van Linthout S; Pryshliak M; Tschöpe C; Klingel K; Kurreck J; Beling A; Fechner H
Circ Heart Fail; 2019 Nov; 12(11):e005250. PubMed ID: 31718319
[TBL] [Abstract][Full Text] [Related]
32. Immunological mechanisms in experimental coxsackievirus B3 myocarditis in mice.
Kishimoto C; Ochiai H; Sasayama S
Jpn Circ J; 1991 Nov; 55(11):1144-8. PubMed ID: 1721094
[TBL] [Abstract][Full Text] [Related]
33. Cardiac injury in myocarditis induced by Coxsackievirus group B, type 3 in Balb/c mice is mediated by Lyt 2 + cytolytic lymphocytes.
Guthrie M; Lodge PA; Huber SA
Cell Immunol; 1984 Oct; 88(2):558-67. PubMed ID: 6091924
[TBL] [Abstract][Full Text] [Related]
34. Nicotine inhibits the production of proinflammatory cytokines of mice infected with coxsackievirus B3.
Li-Sha G; Jing-Lin Z; Li L; Guang-Yi C; Xiao-Wei L; Yue-Chun L
Life Sci; 2016 Mar; 148():9-16. PubMed ID: 26851533
[TBL] [Abstract][Full Text] [Related]
35. Coxsackievirus B3-induced myocarditis. Autoimmunity is L3T4+ T helper cell and IL-2 independent in BALB/c mice.
Estrin M; Huber SA
Am J Pathol; 1987 May; 127(2):335-41. PubMed ID: 3034068
[TBL] [Abstract][Full Text] [Related]
36. A non-cardiovirulent strain of coxsackievirus B3 causes myocarditis in mice with severe combined immunodeficiency syndrome.
Hufnagel G; Chapman N; Tracy S
Eur Heart J; 1995 Dec; 16 Suppl O():18-9. PubMed ID: 8682092
[TBL] [Abstract][Full Text] [Related]
37. Molecular mimicry, anti-coxsackievirus B3 neutralizing monoclonal antibodies, and myocarditis.
Gauntt CJ; Arizpe HM; Higdon AL; Wood HJ; Bowers DF; Rozek MM; Crawley R
J Immunol; 1995 Mar; 154(6):2983-95. PubMed ID: 7533190
[TBL] [Abstract][Full Text] [Related]
38. Development of a new mouse model for coxsackievirus-induced myocarditis by attenuating coxsackievirus B3 virulence in the pancreas.
Pinkert S; Pryshliak M; Pappritz K; Knoch K; Hazini A; Dieringer B; Schaar K; Dong F; Hinze L; Lin J; Lassner D; Klopfleisch R; Solimena M; Tschöpe C; Kaya Z; El-Shafeey M; Beling A; Kurreck J; Van Linthout S; Klingel K; Fechner H
Cardiovasc Res; 2020 Aug; 116(10):1756-1766. PubMed ID: 31598635
[TBL] [Abstract][Full Text] [Related]
39. Involvement of natural killer cells in coxsackievirus B3-induced murine myocarditis.
Godeny EK; Gauntt CJ
J Immunol; 1986 Sep; 137(5):1695-702. PubMed ID: 3018079
[TBL] [Abstract][Full Text] [Related]
40. The effects of FK-506, a novel and potent immunosuppressant, upon murine Coxsackievirus B3 myocarditis.
Hiraoka Y; Kishimoto C; Kurokawa M; Ochiai H; Sasayama S
J Pharmacol Exp Ther; 1992 Mar; 260(3):1386-91. PubMed ID: 1372051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
